Health Condition 1: null- HIV/AIDS
Conditions
Interventions
Intervention1: RADHA 108 Series
and Proline Rich Peptides (PRP): Dose - 0.75 ml each administration,
6 times daily at every 4 hour?s interval
Duration of Therapy - 12 weeks
Control Intervention1: Nil
Sponsors
National AIDS Control Organization NACO
Eligibility
Inclusion criteria
Inclusion criteria: Documentation of HIV infection by any approved ELISA test, and the disease contracted heterosexually (no drug abuse) preferably within six months of participation in this trial. ? With CD4 count greater than 100 cells/cmm ? With a measurable HIV viral load ? Subjects willing to give informed consent for their stay in the hospital and / or follow up visits.
Exclusion criteria
Exclusion criteria: Pregnant or nursing women, women of childbearing potential not using an adequate method of birth control. ? Subjects with kidney failure with Serum Creatinine greater than 1.5 mg/dL. ? With a history of Hepatic Cirrhosis. ? Suffering from Congestive Heart Failure (CHF). ? With current alcohol or substance abuse that could interfere with patient compliance. ? Organ transplant recipient. ? With Preexisting Uncontrolled Seizure Disorder. ? Using long term systemic corticosteroids, Immuno-suppressive and ART.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary outcome measures will be all cause mortality at 3 weeks of 12 weeks therapy showing mark improvement in clinical and physical symptoms of weight gain, absolute CD4 counts and viral load reduction in all HIV positive patients (some opportunistic infections viz TB) and mark improvement in quality of life within first 3 weeks standalone mono-therapy (without ART/DOTS).Timepoint: First 3 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| 12 weeks Receptol alone mono therapy showed mark improvement in quality of life .Timepoint: 12 weeks | — |
Countries
India
Contacts
Public ContactDr Pawan Saharan
Biomix Network Ltd.
Outcome results
None listed